Matrix Metalloproteinase Inhibition Attenuates Atrial Remodeling and Vulnerability to Atrial Fibrillation in a Canine Model of Heart Failure

Cohn, 2004, New therapeutic strategies for heart failure: left ventricular remodeling as a target, J Card Fail, 10, S200, 10.1016/j.cardfail.2004.09.007 Fedak, 2005, Cardiac remodeling and failure: from molecules to man (Part I), Cardiovasc Pathol, 14, 1, 10.1016/j.carpath.2004.12.002 Mann, 2004, Basic mechanisms of left ventricular remodeling: the contribution of wall stress, J Card Fail, 10, S202, 10.1016/j.cardfail.2004.09.008 Boixel, 2003, Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat, J Am Coll Cardiol, 42, 336, 10.1016/S0735-1097(03)00578-3 Moe, 1996, Biatrial appendage hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure, J Card Fail, 2, 127, 10.1016/S1071-9164(96)80031-5 Nakai, 2002, The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery, Am Heart J, 143, 181, 10.1067/mhj.2002.120294 Rossi, 2002, Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy, J Am Coll Cardiol, 40, 1425, 10.1016/S0735-1097(02)02305-7 Khan, 2004, The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure, J Am Coll Cardiol, 43, 68, 10.1016/j.jacc.2003.07.030 O'Brien, 2000, Differential morphometric and ultrastructural remodelling in the left atrium and left ventricle in rapid ventricular pacing-induced heart failure, Can J Cardiol, 16, 1411 Knight, 2003, Atrial fibrillation in patients with congestive heart failure, Pacing Clin Electrophysiol, 26, 1620, 10.1046/j.1460-9592.2003.t01-1-00241.x Maisel, 2003, Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy, Am J Cardiol, 91, 2D, 10.1016/S0002-9149(02)03373-8 Wang, 2003, Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study, Circulation, 107, 2920, 10.1161/01.CIR.0000072767.89944.6E Spach, 1986, Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle. Evidence for electrical uncoupling of side-to-side fiber connections with increasing age, Circ Res, 58, 356, 10.1161/01.RES.58.3.356 Nattel, 2005, Mechanisms of atrial fibrillation: lessons from animal models, Prog Cardiovasc Dis, 48, 9, 10.1016/j.pcad.2005.06.002 Fareh, 1998, Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling, Circulation, 98, 2202, 10.1161/01.CIR.98.20.2202 Gaspo, 1997, Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model, Circulation, 96, 4027, 10.1161/01.CIR.96.11.4027 Li, 1999, Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort, Circulation, 100, 87, 10.1161/01.CIR.100.1.87 Li, 2001, Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure, Circulation, 104, 2608, 10.1161/hc4601.099402 Benjamin, 2001, Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease, J Investig Med, 49, 381, 10.2310/6650.2001.33783 Vu, 2000, Matrix metalloproteinases: effectors of development and normal physiology, Genes Dev, 14, 2123, 10.1101/gad.815400 Verma, 2007, Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs, Bioorg Med Chem, 15, 2223, 10.1016/j.bmc.2007.01.011 Spinale, 2002, Matrix metalloproteinases: regulation and dysregulation in the failing heart, Circ Res, 90, 520, 10.1161/01.RES.0000013290.12884.A3 Shastry, 2003, Matrix metalloproteinase in left ventricular remodeling and heart failure, Curr Cardiol Rep, 5, 200, 10.1007/s11886-003-0049-5 Sierevogel, 2003, Matrix metalloproteinases: a therapeutic target in cardiovascular disease, Curr Pharm Des, 9, 1033, 10.2174/1381612033455099 Spinale, 1999, Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function, Circ Res, 85, 364, 10.1161/01.RES.85.4.364 Apple, 2006, Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling, J Cardiovasc Pharmacol, 47, 228, 10.1097/01.fjc.0000200989.23987.b8 Laurent, 2008, Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model, Cardiovasc Res, 77, 89, 10.1093/cvr/cvm024 Laurent, 2008, Experimental studies of atrial fibrillation: comparison of two pacing models, Am J Physiol Heart Circ Physiol, 294, H1206, 10.1152/ajpheart.00999.2007 Laurent, 2008, Simultaneous right atrioventricular pacing: a novel model to study atrial remodeling and atrial fibrillation in the setting of heart failure, J Card Fail, 14, 254, 10.1016/j.cardfail.2007.10.021 Pikul, 1999, Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases, J Med Chem, 42, 87, 10.1021/jm980142s King, 2003, Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure, Circ Res, 92, 177, 10.1161/01.RES.0000052312.41419.55 Louie, 1998, “Stunning” of the left atrium after spontaneous conversion of atrial fibrillation to sinus rhythm: demonstration by transesophageal Doppler techniques in a canine model, J Am Coll Cardiol, 32, 2081, 10.1016/S0735-1097(98)00508-7 Howard, 1991, Sequential echocardiographic-Doppler assessment of left ventricular remodelling and mitral regurgitation during evolving experimental heart failure, Cardiovasc Res, 25, 468, 10.1093/cvr/25.6.468 Moe, 1990, Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure, Cardiovasc Res, 24, 570, 10.1093/cvr/24.7.570 Courtman, 2004, Inward remodeling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline, J Vasc Res, 41, 157, 10.1159/000077145 Koura, 2002, Anisotropic conduction properties in canine atria analyzed by high-resolution optical mapping: preferential direction of conduction block changes from longitudinal to transverse with increasing age, Circulation, 105, 2092, 10.1161/01.CIR.0000015506.36371.0D Maquart, 1993, In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds, J Clin Invest, 92, 2368, 10.1172/JCI116842 Xu, 2004, Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation, Circulation, 109, 363, 10.1161/01.CIR.0000109495.02213.52 Shinagawa, 2002, Consequences of atrial tachycardia-induced remodeling depend on the preexisting atrial substrate, Circulation, 105, 251, 10.1161/hc0202.102014 Li, 2000, Effects of experimental heart failure on atrial cellular and ionic electrophysiology, Circulation, 101, 2631, 10.1161/01.CIR.101.22.2631 Corbel, 2001, Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat, J Pathol, 193, 538, 10.1002/path.826 Falk, 2002, Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury, Eur J Cardiothorac Surg, 22, 53, 10.1016/S1010-7940(02)00207-5 Li, 2002, MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure, Am J Physiol Heart Circ Physiol, 282, H983, 10.1152/ajpheart.00233.2001 Li, 2000, Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy, Proc Natl Acad Sci U S A, 97, 12746, 10.1073/pnas.97.23.12746 Siwik, 2000, Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro, Circ Res, 86, 1259, 10.1161/01.RES.86.12.1259 Moe, 2004, In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure, Am J Physiol Heart Circ Physiol, 287, H1813, 10.1152/ajpheart.00036.2004 Bradham, 2002, TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling, Am J Physiol Heart Circ Physiol, 282, H1288, 10.1152/ajpheart.00526.2001 Cleland, 2005, Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER 5, Eur J Heart Fail, 7, 931, 10.1016/j.ejheart.2005.04.002 Peterson, 2006, The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors, Cardiovasc Res, 69, 677, 10.1016/j.cardiores.2005.11.032 Spinale, 1998, Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function, Circ Res, 82, 482, 10.1161/01.RES.82.4.482